Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Amadeo 42, 20133, Milan, Italy.
Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133, Milan, Italy.
J Exp Clin Cancer Res. 2019 Feb 4;38(1):51. doi: 10.1186/s13046-019-1060-z.
Radiotherapy is one of the main treatment options for non-metastatic prostate cancer (PCa). Although treatment technical optimization has greatly improved local tumor control, a considerable fraction of patients still experience relapse due to the development of resistance. Radioresistance is a complex and still poorly understood phenomenon involving the deregulation of a variety of signaling pathways as a consequence of several genetic and epigenetic abnormalities. In this context, cumulative evidence supports a functional role of microRNAs in affecting radioresistance, suggesting the modulation of their expression as a novel radiosensitizing approach. Here, we investigated for the first time the ability of miR-205 to enhance the radiation response of PCa models.
miR-205 reconstitution by a miRNA mimic in PCa cell lines (DU145 and PC-3) was used to elucidate miR-205 biological role. Radiation response in miRNA-reconstituted and control cells was assessed by clonogenic assay, immunofluorescence-based detection of nuclear γ-H2AX foci and comet assay. RNAi was used to silence the miRNA targets PKCε or ZEB1. In addition, target-protection experiments were carried out using a custom oligonucleotide designed to physically disrupt the pairing between the miR-205 and PKCε. For in vivo experiments, xenografts generated in SCID mice by implanting DU145 cells stably expressing miR-205 were exposed to 5-Gy single dose irradiation using an image-guided animal micro-irradiator.
miR-205 reconstitution was able to significantly enhance the radiation response of prostate cancer cell lines and xenografts through the impairment of radiation-induced DNA damage repair, as a consequence of PKCε and ZEB1 inhibition. Indeed, phenocopy experiments based on knock-down of either PKCε or ZEB1 reproduced miR-205 radiosensitizing effect, hence confirming a functional role of both targets in the process. At the molecular level, miR-205-induced suppression of PKCε counteracted radioresistance through the impairment of EGFR nuclear translocation and the consequent DNA-PK activation. Consistently, disruption of miR-205-PKCε 3'UTR pairing almost completely abrogated the radiosensitizing effect.
Our results uncovered the molecular and cellular mechanisms underlying the radiosensitizing effect of miR-205. These findings support the clinical interest in developing a novel therapeutic approach based on miR-205 reconstitution to increase PCa response to radiotherapy.
放射疗法是治疗非转移性前列腺癌(PCa)的主要方法之一。尽管治疗技术的优化极大地提高了局部肿瘤控制率,但仍有相当一部分患者由于耐药性的发展而复发。放射抗性是一种复杂且仍未被充分理解的现象,涉及多种信号通路的失调,这是由于多种遗传和表观遗传异常所致。在这种情况下,越来越多的证据支持 microRNA 在影响放射抗性方面具有功能作用,这表明调节其表达是一种新的放射增敏方法。在这里,我们首次研究了 miR-205 增强 PCa 模型放射反应的能力。
在 PCa 细胞系(DU145 和 PC-3)中使用 miRNA 模拟物进行 miR-205 的重建,以阐明 miR-205 的生物学作用。通过集落形成实验、基于免疫荧光的核 γ-H2AX 焦点检测和彗星实验评估 miRNA 重建和对照细胞中的放射反应。使用靶向 PKCε 或 ZEB1 的 RNAi 沉默 miRNA 靶标。此外,使用设计用于物理破坏 miR-205 与 PKCε 之间配对的定制寡核苷酸进行靶标保护实验。对于体内实验,将稳定表达 miR-205 的 DU145 细胞植入 SCID 小鼠中生成异种移植物,然后使用图像引导动物微辐射器对其进行 5-Gy 单次剂量照射。
miR-205 的重建能够通过抑制 PKCε 和 ZEB1 抑制放射诱导的 DNA 损伤修复,显著增强前列腺癌细胞系和异种移植物的放射反应。事实上,基于敲低 PKCε 或 ZEB1 的表型复制实验重现了 miR-205 的放射增敏作用,从而证实了这两个靶标在该过程中的功能作用。在分子水平上,miR-205 诱导的 PKCε 抑制通过抑制 EGFR 核易位和随后的 DNA-PK 激活来对抗放射抗性。一致地,破坏 miR-205-PKCε 3'UTR 配对几乎完全消除了放射增敏作用。
我们的结果揭示了 miR-205 放射增敏作用的分子和细胞机制。这些发现支持了基于 miR-205 重建开发新的治疗方法以增加 PCa 对放疗反应的临床兴趣。